Table 1.
Differences in any Drug Use/Misuse by Study Arm to Baseline Versus 3-Month Follow-up
| Control Arm (n = 327) |
Treatment Arm (n = 306) |
||||||
|---|---|---|---|---|---|---|---|
| Substance categories | Baseline, % |
3-Month Follow-up, % |
Baseline -3-Month Follow-up, Δ1% (95% CI) |
Baseline, % |
3-Month Follow-up % |
Baseline -3-Month Follow-up, Δ2% (95% CI) |
Control Arm - Treatment Arm, Δ1% - Δ2% (95% CI) |
| Marijuana | 82.9 | 69.0 | 13.9 (9.0 to 18.0) | 81.1 | 63.7 | 17.4 (12.0 to 22.0) | −3.5 (−10.0 to 3.0) |
| Cocaine or crack | 22.7 | 13.8 | 8.9 (5.0 to 13.0) | 21.3 | 14.1 | 7.2 (3.0 to 11.0) | 1.7 (−4.0 to 8.0) |
| Methamphetamines | 5.9 | 3.7 | 2.2 (−1.0 to 5.0) | 4.3 | 2.3 | 2.0 (0.0 to 4.0) | 0.2 (−3.0 to 4.0) |
| Inhalants | 3.4 | 2.2 | 1.2 (0.0 to 3.0) | 2.6 | 2.0 | 0.6 (−1.0 to 3.0) | 0.6 (−2.0 to 3.0) |
| Hallucinogens | 5.6 | 4.6 | 1.0 (−2.0 to 4.0) | 3.3 | 2.3 | 1.0 (−1.0 to 3.0) | 0.0 (−3.0 to 3.0) |
| Illicit opioids | 10.5 | 6.2 | 4.3 (1.0 to 8.0) | 8.9 | 8.9 | 0.0 (−3.0 to 3.0) | 4.3 (0.0 to 9.0) |
| Gamma hydroxybutyrate (GHB) | 0.9 | 0.6 | 0.3 (−1.0 to 1.0) | 0.3 | 0.7 | −0.4 (−1.0 to 0.0) | −0.1 (−1.0 to 2.0) |
| Amphetamines | 6.2 | 5.3 | 0.9 (−2.0 to 4.0) | 6.6 | 3.0 | 3.6 (1.0 to 6.0) | −2.7 (−7.0 to 1.0) |
| Benzodiazepines | 16.3 | 14.0 | 2.3 (−2.0 to 7.0) | 13.1 | 8.9 | 4.2 (0.0 to 8.0) | −1.9 (−8.0 to 4.0) |
| Barbiturates | 1.5 | 0.6 | 0.9 (−1.0 to 3.0) | 0.7 | 0.7 | 0.0 (−1.0 to 1.0) | 0.9 (−1.0 to 3.0) |
| Methadone | 5.5 | 4.7 | 0.8 (−2.0 to 4.0) | 5.9 | 4.9 | 1.0 (−2.0 to 4.0) | −0.2 (−4.0 to 4.0) |
| Prescription opioids | 24.6 | 20.5 | 4.1 (−1.0 to 9.0) | 21.7 | 15.5 | 6.2 (2.0 to 10.0) | −2.1 (−9.0 to 4.0) |
| Total drugs including marijuana | 100.0 | 84.1 | 15.9 (12.0 to 20.0) | 100.0 | 77.8 | 22.2 (18.0 to 27.0) | −6.3 (−13.0 to 0.0) |
| Total drugs excluding marijuana | 48.6 | 40.1 | 8.5 (3.0 to 14.2) | 43.5 | 30.1 | 13.4 (8.4 to 18.2) | −4.9 (−12.5 to 2.8) |